With the exception of the δ-targeted drugs, because of modest clinical effects observed so far with single agent PI3K inhibitors — certainly less than is seen with BRAF, MEK, EGFR and ALK inhibitors in the corresponding vulnerable genotypes — it is important that rational combinations of PI3K inhibitors are pursued to maximize the chances of revealing their full therapeutic potential in cancer patients. This evidence concerns the gene PIK3CB and cancer.